抗氧化剂对冠状动脉疾病成年患者的氧化应激的影响:系统性审查
Islam M Alhusban1, Misook L Chung2, Martha Biddle1
1College of Nursing, University of Kentucky 751 Rose Street Lexington, Kentucky 40536.
Clinical nutrition ESPEN
|September 6, 2025
概括
抗氧化剂可以降低冠状动脉疾病患者的氧化应激. 这项系统性审查发现各种抗氧化剂是有效的,但需要更多标准化的研究才能得出关于它们益处的最终结论.
科学领域:
- 心血管医学
- 营养生物化学
- 氧化应激研究
背景情况:
- 氧化应激 (OS) 是冠状动脉疾病 (CAD) 发病的一个关键因素,促进动脉硬化斑块的发展.
- 已知抗氧化剂通过抑制自由基的产生来减轻OS.
- 对抗氧化剂对CAD患者的生存系统的影响缺乏全面的,最新的系统审查.
研究的目的:
- 在被诊断为冠状动脉疾病的成年患者中,系统地审查和确定外源抗氧化剂对氧化应激水平的影响.
主要方法:
- 在2013年1月至2025年5月期间发表的随机对照试验 (RCT) 的系统审查.
- 搜索的数据库包括PubMed,Medline和CINAHL的相关研究.
- 排除标准:患有炎症,/肝功能衰竭或近期重大手术的参与者.
主要成果:
- 十五个RCT符合2338项初步研究的纳入标准.
- 九项关于补充抗氧化剂的研究 (L- 卡尼丁,黑激素) 和两项关于饮食抗氧化剂的研究 (霍拉桑小麦,葡萄酒) 显示显著的OS降低 (P<0.05).
- 静脉注射的抗氧化剂 (阿尔法脂酸,维生素C,N- 乙半氨酸) 也显著降低了生存率.
结论:
- 证据表明抗氧化剂可能会降低冠状动脉疾病患者的氧化应激.
- 包括各种抗氧化剂和OS生物标志物在内的研究方法的异质性限制了最终的结论.
- 需要对标准化干预措施和结果进行进一步的研究,以确认抗氧化剂在CAD中的有效性.
更多相关视频
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.3K
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.6K
相关概念视频
01:30Coronary Artery Disease I: Introduction
54
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
01:26Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:28Acute Coronary Syndrome IV: Interprofessional Care
25
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
25
01:26Coronary Artery Disease II: Pathophysiology
33
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
33
01:27Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30